What Happened
- The Telangana government announced a free Human Papillomavirus (HPV) vaccination programme for girls aged 14 and 15, to be rolled out starting February 28, 2026.
- The programme targets approximately 3.5 to 4 lakh girls in the state and will be implemented over three months in the initial phase.
- The vaccine being administered is Gardasil 4, a quadrivalent HPV vaccine that protects against HPV types 6, 11, 16, and 18 — the strains responsible for the majority of cervical cancers. In the private sector, each dose costs between Rs 2,000 and Rs 4,000, making free public provision a significant financial intervention.
- Cervical cancer is the second most common cancer among women in Telangana, with approximately 3,200 new cases recorded annually. The state recorded 3,169 cases in 2021, rising to 3,233 in 2025, as reported in Parliament in February 2026.
- The launch is aligned with the Union Budget 2024 commitment to introduce HPV vaccination into the Universal Immunisation Programme (UIP) and with the World Health Organisation's 2030 target of vaccinating 90% of girls against HPV by age 15.
- The nationwide HPV programme rollout in February 2026 is estimated to open a Rs 1,300 crore annual procurement market, with India sourcing doses through Gavi (the Vaccine Alliance) and from domestic manufacturers.
Static Topic Bridges
Human Papillomavirus (HPV) and Cervical Cancer — Scientific Context
Human Papillomavirus is a group of related viruses transmitted through skin-to-skin contact, primarily sexual contact. Most HPV infections are cleared naturally by the immune system, but persistent infection with high-risk strains — particularly HPV types 16 and 18 — can lead to cervical cancer over a period of years. Globally, HPV types 16 and 18 account for approximately 70% of all cervical cancers, and that figure rises to 85% in India.
- HPV types 6 and 11: low-risk strains responsible for genital warts.
- HPV types 16 and 18: high-risk oncogenic strains responsible for the majority of cervical cancers.
- India contributes one-fifth of the global burden of cervical cancer.
- Crude cervical cancer incidence in India: approximately 18.7 per 100,000 women.
- WHO 2030 target: eliminate cervical cancer as a public health threat; reduce incidence to below 4 per 100,000 women.
- The quadrivalent vaccine (Gardasil 4) protects against all four major strains (6, 11, 16, 18); bivalent vaccines protect against 16 and 18 only.
Connection to this news: Telangana's programme specifically targets the 14–15 age group — before the typical age of sexual activity — as the HPV vaccine is most effective when administered prior to any HPV exposure, maximising protective immunity.
Universal Immunisation Programme (UIP) — India's Vaccine Delivery Framework
India's Universal Immunisation Programme, launched in 1985 and expanded progressively, is one of the largest public health programmes in the world. It currently covers vaccines against 12 vaccine-preventable diseases, delivered to approximately 2.67 crore newborns and 2.9 crore pregnant women annually. The inclusion of HPV vaccine in the UIP was recommended by the National Technical Advisory Group on Immunisation (NTAGI) and committed in the Union Budget 2024.
- UIP covers: BCG, OPV, Hepatitis B, DPT, Hib, Rotavirus, PCV, MMR, IPV, Japanese Encephalitis (in endemic areas), and now HPV.
- NTAGI recommendation: one-time catch-up for girls aged 9–14 years; routine introduction at age 9.
- School-based delivery is the primary mode: Grade 5 through Grade 10 coverage.
- Government plans to vaccinate 1.15 crore girls annually during the three-year catch-up phase, with approximately 2.6 crore doses by 2027.
- Over 1 crore doses of Gardasil are being procured through Gavi, the Vaccine Alliance, in the initial phase.
Connection to this news: Telangana's state-level programme is part of India's broader push to fulfil its UIP commitment on HPV vaccination. By targeting 14–15-year-olds free of cost, the state is aligned with NTAGI recommendations while filling a gap ahead of full national rollout.
Women's Health and Preventive Care — Policy Dimensions
Cervical cancer disproportionately affects women from lower socio-economic backgrounds in India, who lack access to screening (Pap smear, HPV DNA test) and early treatment. Preventive vaccination is thus a social equity intervention as much as a public health measure. The Ayushman Bharat Health and Wellness Centres (HWCs) have been tasked with expanding cancer screening at the primary care level, and the PM National Digital Health Mission (NDHA) is building the infrastructure for tracking vaccination and screening records.
- Cervical cancer is the second most common cancer among Indian women (after breast cancer).
- India accounts for approximately 20% of global cervical cancer deaths.
- Targeted screen-and-treat approaches (via HWCs) complement vaccination to reduce the existing burden among older unvaccinated women.
- The National Cancer Control Programme (NCCP) supports state-level cancer screening and treatment.
- Rashtriya Bal Swasthya Karyakram (RBSK) provides child health screening; HPV vaccination integrates with school health platforms.
Connection to this news: Telangana's choice of the 14–15 age bracket — girls in secondary school — is a deliberate social targeting strategy. School enrolment at this age is relatively high, enabling efficient delivery, while the free provision directly addresses the affordability barrier that has historically left this intervention out of reach for low-income families.
Gavi, the Vaccine Alliance — Global Vaccine Access Architecture
Gavi, the Vaccine Alliance, is a public-private global health partnership established in 2000 to improve access to vaccines in low- and middle-income countries. It brings together the World Health Organization, UNICEF, the World Bank, the Bill and Melinda Gates Foundation, civil society organisations, and vaccine manufacturers. Gavi supports countries through co-financing of vaccine procurement, technical assistance, and cold chain strengthening. India, which was a Gavi-supported country until 2016, now participates as a donor and procurement partner for certain vaccines.
- Gavi was established in 2000; headquartered in Geneva.
- Supports 57 lower-income countries with subsidised vaccine procurement.
- India transitioned out of Gavi funding eligibility in 2016 (income threshold crossed) but remains a procurement partner.
- Gavi has supported HPV vaccine introduction in over 45 countries.
- India procuring over 1 crore Gardasil doses through Gavi channels for the initial national HPV rollout.
Connection to this news: India's partial use of Gavi procurement channels for the initial HPV rollout leverages Gavi's negotiated pricing with Merck (Gardasil manufacturer), helping the government manage the cost of a large-scale free vaccination drive — a model that Telangana's programme is embedded within.
Key Facts & Data
- Telangana HPV programme launch: February 28, 2026.
- Target group: Girls aged 14–15; approximately 3.5–4 lakh girls over three months.
- Vaccine: Gardasil 4 (quadrivalent) — protects against HPV types 6, 11, 16, 18.
- Private sector cost: Rs 2,000–4,000 per dose; provided free under this programme.
- Telangana cervical cancer burden: approximately 3,200 women affected annually (2nd most common cancer in state).
- Cases in Telangana: 3,169 (2021) → 3,233 (2025) per MoHFW data shared in Parliament, February 2026.
- HPV types 16 and 18: account for 70% of cervical cancers globally, 85% in India.
- India contributes approximately one-fifth of global cervical cancer cases.
- WHO 2030 target: vaccinate 90% of girls against HPV by age 15.
- National plan: 1.15 crore girls vaccinated per year during the catch-up phase; 2.6 crore doses by 2027.
- National HPV rollout estimated to create Rs 1,300 crore annual vaccine procurement market.
- UIP established 1985; currently covers 12 vaccine-preventable diseases.